Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOX vs FL in Stage II and III Colon Cancer
NCT00004931Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2000
- Primary completion
- Sep 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxaliplatin in colon cancer (2 arms), sponsored by National Cancer Institute. Primary endpoint: Disease-Free Survival at 3 years. Started Feb 2000; status: completed.
02
Drugs
oxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT00004931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004931.